Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | AML haplo-HSCT outcomes

Ali Bazarbachi • 23 Aug 2020
EBMT 2020
Acute Myeloid Leukemia Leukemia Busulfan Cyclophosphamide Fludarabine Thiotepa

Ali Bazarbachi, MD, PhD, American University of Beirut Medical Center, Beirut, Lebanon, discusses the results of a study evaluating the outcomes of acute myeloid leukemia (AML) patients receiving a haploidentical hematopoietic stem cell transplant (haplo-HSCT) with thiotepa/busulfan/fludarabine (TBF) conditioning and post-transplant cyclophosphamide versus a matched unrelated donor with fludarabine/busulfan conditioning. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Ali Bazarbachi

6:52
Somatic mutations that impact alloSCT outcomes in patients with AML
Ali Bazarbachi • 19 Dec 2023
8:11
Improvements over time in elderly patients with AML treated with alloSCT: an EBMT Registry study
Ali Bazarbachi • 19 Dec 2023
11:16
Latest advancements in alloHSCT for ALL
Ali Bazarbachi • 21 Mar 2022
9:06
Advances in the management of R/R Hodgkin lymphoma
Ali Bazarbachi • 28 Sep 2021

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals